Compass Therapeutics, Inc.
CMPXNasdaq
$2.05
↓ -2.4%Jul 17 close · end-of-day
Price
1Y↓ -34.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$382.1M
Enterprise Value
$187.4M
P/E
—
P/S
—
P/B
2.0
EV/EBITDA
—
PEG
—
FCF Yield
-14.0%
Dividend Yield
—
Revenue (TTM)
$0.00
Net Income (TTM)
-$68.2M
Free Cash Flow (TTM)
-$53.3M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-36.6%
ROIC
—
Debt / Equity
—
Net Cash
$194.7M
Return 1Y
-34.9%
Company profile
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops proprietary antibody-based therapeutics to treat multiple human diseases. The company's product candidates include CTX-009, an investigational bispecific antibody, which is in Phase II clinical trial for biliary tract cancers, as well as Phase Ib clinical trials for colorectal and ovarian cancer.
- CEO
- Thomas J. Schuetz
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 20
- Headquarters
- Massachusetts
- Website
- compasstherapeutics.com
Management & directors
- Anderman JonathanGeneral Counsel
- Lerner NeilChief Accounting Officer
- Schuetz Thomas J.CHIEF EXECUTIVE OFFICER
- Shin BarryCFO
Roles derived from SEC Form 4 filings.
Earnings
CMPX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS——
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0.00 | $850,000.00 | $0.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$27.8M | -$81.9M | -$41.7M | -$50.4M | -$56.6M | -$72.8M |
| Net income | -$29.5M | -$82.2M | -$39.2M | -$42.5M | -$49.4M | -$66.5M |
| Diluted EPS | — | — | — | — | — | — |
| Operating cash flow | -$26.8M | -$19.7M | -$34.1M | -$40.6M | -$44.9M | -$49.1M |
| Free cash flow | -$26.9M | -$21.2M | -$34.3M | -$40.6M | -$44.9M | -$49.2M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | -6661.8% | — |
| Net margin | — | — | — | — | -5808.8% | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $850,000.00 | $0.00 | — | — | $0.00 | $0.00 | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$15.0M | -$12.2M | -$16.6M | -$18.0M | -$21.1M | -$15.8M | -$18.0M | -$20.3M |
| Net income | -$13.1M | -$10.5M | -$15.0M | -$16.6M | -$19.9M | -$14.3M | -$15.7M | -$18.3M |
| Diluted EPS | — | — | — | — | — | — | — | — |
| Operating cash flow | -$10.8M | -$11.1M | -$9.2M | -$13.2M | -$11.8M | -$10.8M | -$13.3M | -$17.3M |
| Free cash flow | -$10.8M | -$11.1M | -$9.2M | -$13.2M | -$11.8M | -$10.9M | -$13.3M | -$17.4M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -1770.0% | — | — | — | — | — | — | — |
| Net margin | -1538.4% | — | — | — | — | — | — | — |
Company news
Jul 3, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-04-29 | Anderman Jonathan· General Counsel | Buy | 25,000 | $1.89 | $47,250.00 | filing |
| 2026-04-29 | Anderman Jonathan· General Counsel | Award | 25,000 | $1.89 | $47,250.00 | filing |
| 2026-04-29 | Lerner Neil· Chief Accounting Officer | Buy | 15,000 | $1.89 | $28,350.00 | filing |
| 2026-04-29 | Lerner Neil· Chief Accounting Officer | Award | 15,000 | $1.89 | $28,350.00 | filing |
| 2026-02-08 | Schuetz Thomas J.· CHIEF EXECUTIVE OFFICER | Tax withholding | 36,687 | $6.52 | $239,199.24 | filing |
| 2026-01-09 | Schuetz Thomas J.· CHIEF EXECUTIVE OFFICER | Tax withholding | 46,777 | $5.35 | $250,256.95 | filing |
| 2026-01-02 | Schuetz Thomas J.· CEO | Award | 250,000 | $5.17 | $1.3M | filing |
| 2026-01-02 | Anderman Jonathan· General Counsel | Award | 150,000 | $5.17 | $775,500.00 | filing |
| 2026-01-02 | Shin Barry· CFO | Award | 125,000 | $5.17 | $646,250.00 | filing |
| 2026-01-02 | Lerner Neil· Chief Accounting Officer | Award | 62,500 | $5.17 | $323,125.00 | filing |
| 2025-11-16 | Schuetz Thomas J.· CHIEF EXECUTIVE OFFICER | Tax withholding | 44,025 | $4.83 | $212,640.75 | filing |
Latest 11 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.